Tag Archives: Ram Selvaraju

Abeona Therapeutics (ABEO) Has a New Rating from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright initiated coverage with a Buy rating on Abeona Therapeutics (ABEO – Research Report) and a price target of $11.00. The company’s shares closed last Monday at $2.54, close to its

Spero Therapeutics (SPRO) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Spero Therapeutics (SPRO – Research Report) today and set a price target of $35.00. The company’s shares closed last Monday at $8.89, close to its 52-week low of $7.99. According

Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM) and Baudax Bio (NASDAQ: BXRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Axsome Therapeutics (AXSM – Research Report) and Baudax Bio (BXRX – Research Report) with bullish sentiments. Axsome Therapeutics (AXSM) In a report

Repligen (RGEN) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Repligen (RGEN – Research Report) today and set a price target of $110.00. The company’s shares closed last Monday at $97.88, close to its 52-week high of $99.25. According to

H.C. Wainwright Keeps a Buy Rating on Synlogic (SYBX)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Synlogic (SYBX – Research Report), with a price target of $13.00. The company’s shares closed last Monday at $2.69, close to its 52-week low of

Analysts Offer Insights on Healthcare Companies: Enlivex Therapeutics (NASDAQ: ENLV), Amarin (NASDAQ: AMRN) and Bio-Path Holdings (NASDAQ: BPTH)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enlivex Therapeutics (ENLV – Research Report), Amarin (AMRN – Research Report) and Bio-Path Holdings (BPTH – Research Report) with bullish sentiments. Enlivex